Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lonsurf
Combination of Lonsurf and Irinotecan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Combination of Lonsurf® and Irinotecan |
| Name | Type | Description |
|---|---|---|
| Combination of Lonsurf® and Irinotecan | COMBINATION_PRODUCT | Trifluridine/Tipiracil (Lonsurf®) and Irinotecan * Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle. * Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose. |
Inclusion Criteria: 1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) prior to performing any protocol-related procedures, including screening evaluations 2. Age ≥ 18 years at time of study entry 3....
Top 20 of 23 competitors
The combination of Lonsurf and Irinotecan is being studied for use in cholangiocarcinoma and metastatic colorectal cancer. It is an investigational small molecule combination in Phase 2 clinical development, evaluated in patients with these advanced gastrointestinal cancers.
The combination of Lonsurf and Irinotecan targets cancer cells through the mechanisms of trifluridine/tipiracil and irinotecan. Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, while irinotecan inhibits topoisomerase I, together disrupting cancer cell replication.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is developing the combination of Lonsurf and Irinotecan. The company is conducting clinical trials to evaluate this combination in patients with cholangiocarcinoma and metastatic colorectal cancer.
The combination of Lonsurf and Irinotecan is in Phase 2 clinical development. It is investigational and not yet approved by regulatory authorities. Two Phase 2 trials are listed, one completed and one currently recruiting participants.
The combination is studied in NCT04059562, a completed Phase 2 trial in cholangiocarcinoma, and NCT06245356, a recruiting Phase 2 trial in metastatic colorectal cancer and gastroesophageal cancer with DPD deficiency. Both are open-label, non-randomized studies.
The combination of Lonsurf and Irinotecan includes Lonsurf, which is the brand name for trifluridine/tipiracil. Lonsurf is one component of the combination, and irinotecan is added to it in the studied regimen.